Sort
11,323 grants matching “glioblastoma”
Automatic Volumetric Treatment Response Assessment and Determination of Regional Genetic Characteristics in Glioblastoma
$5,067Ken Chang · Harvard Medical School · F30 · FY2019 · CA
Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma
$5,037Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2024 · NS
Genomics
$4,923Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2018 · CA
Interactions between NEDD9, AURKA, and p53 in mammary tumor development
$4,847Joy L. Little · Research Inst Of Fox Chase Can Ctr · F32 · FY2011 · CA
Immunology & Cancer Immunotherapy (ICI)
$4,790Charles L Sentman · Dartmouth College · P30 · FY2018 · CA
MICROGLIA ACTIVATION IN RESPONSE TO BLOOD-BRAIN BARRIER DISRUPTION IN THE CNS
$4,675Katerina Akassoglou · University Of California, San Diego · P41 · FY2009 · RR
Study of Pyrazolacridine (PZA) in Adults with Glioblastoma Multiforme
$4,616University Of Pennsylvania · M01 · FY2004 · RR
Translational Therapeutics Research Program (TT)
$4,572David P Carbone · Ohio State University · P30 · FY2018 · CA
Cellular and molecular mechanisms regulating glial growth control and survival
$4,524Jaeda Coutinho-Budd · Univ Of Massachusetts Med Sch Worcester · F32 · FY2014 · NS
Phase 2 Study of PTC299 in Glioblastoma Multiforme (IND 71,033)
$4,351Jay A Barth · Ptc Therapeutics, Inc. · R01 · FY2010 · FD
ROLE OF CD133 IN TUMORIGENESIS
$4,291Frank Patrick McCormick · University Of California, San Francisco · P41 · FY2011 · RR
LCCC 0424: PHASE I ERLOTINIB GIVEN EVERY 72 HOURS TO PATIENTS WITH GLIOBLASTOMA
$4,127Celeste M Lindley · Univ Of North Carolina Chapel Hill · M01 · FY2007 · RR
ARSENIC TRIOXIDE AND STEREOTACTIC RADIOSURGERY/RADIOTHERAPY IN MALIGNANT GLIOMA
$4,095Iris Catrice Gibbs · Stanford University · M01 · FY2007 · RR
High-throughput screen for specific small-molecule inhibitors of HIF-2A activity
$3,950Mei Yee Koh · University Of Tx Md Anderson Can Ctr · R03 · FY2013 · DA
Program 11: Cancer Immunology
$3,833Arlene H Sharpe · Dana-Farber Cancer Inst · P30 · FY2018 · CA
MICROGLIA ACTIVATION IN RESPONSE TO BLOOD-BRAIN BARRIER DISRUPTION IN THE CNS
$3,820Katerina Akassoglou · University Of California, San Diego · P41 · FY2011 · RR
Tumor Progression and Recurrence (01)
$3,608Boris Pasche · Wake Forest University Health Sciences · P30 · FY2018 · CA
MICROGLIA ACTIVATION IN RESPONSE TO BLOOD-BRAIN BARRIER DISRUPTION IN THE CNS
$3,592Katerina Akassoglou · University Of California, San Diego · P41 · FY2010 · RR
RECURRENT TEMOZOLOMIDE-RESISTANT MALIGNANT GLIOMAS
$3,564Timothy Cloughesy · University Of California Los Angeles · M01 · FY2008 · RR
CLINICAL TRIAL: A PHASE I TRIAL OF CAPECITABINE RAPIDLY DISINTEGRATING TABLETS A
$3,555Susan M Blaney · Baylor College Of Medicine · M01 · FY2009 · RR
ROLE OF CD133 IN TUMORIGENESIS
$3,533Frank Patrick McCormick · University Of California, San Francisco · P41 · FY2010 · RR
Developmental Funds
$3,500Alan Ashworth · University Of California, San Francisco · P30 · FY2018 · CA
Phase I/II ZD1839 in Astrocytoma or Glioblastoma and Meningioma
$3,467University Of Wisconsin Madison · M01 · FY2004 · RR
PHASE II TRIAL OF POLY-ICLC FOR GLIOBLASTOMA [NABTC 01-05]
$3,465University Of California Los Angeles · M01 · FY2005 · RR
Role of Human Cerebrospinal Fluid Chemokines in the Invasiveness of Human Glioblastoma
$3,443Hugo Guerrero-Cazares · Mayo Clinic Jacksonville · R21 · FY2017 · CA